Startups
Bonum Therapeutics
Bonum Therapeutics develops dual-binding antibody medicines whose therapeutic activity switches on when a sensor binds a specified target and switches off when the molecule disengages. It uses this reversible regulation to concentrate cytokine activity in tumors and reduce effects elsewhere in the body. Its initial programs target cancer, with potential applications in autoimmune disease, metabolic disorders and pain. Bonum continued the team and retained platform of Good Therapeutics after Roche acquired that predecessor’s PD-1-regulated IL-2 program in 2022; the companies and financings are distinct.
Founded 2022
Team
Cindy YeeVice President, Corporate Strategy & Operations |
Diane HollenbaughChief Scientific Officer |
Gaurav AggarwalBoard Member |
John McKearnBoard Member |
John MulliganFounder and Chief Executive Officer; Board Member |
Justin KillebrewVice President of Biology |
Karl HandelsmanBoard Member |
Linda LiangVice President, Antibody Discovery |
 Mitchell MutzIndependent Director |
 Monique SchiersingBoard Member |
Neela PatelChief Business Officer |
Nicholas WalrodBoard Member |
Rhonda KnudsenDirector of Business Operations |
Samuel BjorkExecutive Chair |
 Samuel C. BlackmanIndependent Director |